CLHC1 and lung adenocarcinoma: To date, the FDA has approved 5 ALK-TKIs: crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib.[3,4] Herein, we first identified a novel CLHC1/RNT4 intergenic region–ALK fusion in a patient with lung adenocarcinoma (LUAD) with brain metastasis (BM), who benefited from crizotinib and endostar sequential alectinib.